Caring Brands, Inc. (NASDAQ:CABR) Stock Short Interest Report for October

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 2,863 shares, a decline of 55.5% from the September 30th total of 6,427 shares. Based on an average daily volume of 35,362 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Caring Brands in a research report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has an average rating of “Sell”.

Caring Brands Stock Performance

Shares of NASDAQ CABR traded up $0.04 during midday trading on Friday, reaching $1.11. The company’s stock had a trading volume of 33,492 shares, compared to its average volume of 89,201. The company has a market cap of $11.66 million and a P/E ratio of -1.51. The business’s 50 day moving average price is $1.23 and its two-hundred day moving average price is $1.15. Caring Brands has a fifty-two week low of $0.71 and a fifty-two week high of $5.35.

Caring Brands (NASDAQ:CABR) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Caring Brands stock. Susquehanna International Group LLP purchased a new stake in Caring Brands, Inc. (NASDAQ:CABR) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,771 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned approximately 0.20% of Caring Brands as of its most recent SEC filing.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.